



COVID-19: Precision Medicine and Vascular Endothelium

This is the peer reviewed version of the following article:
Original:
Tricarico, G., Travagli, V. (2021). COVID-19: Precision Medicine and Vascular Endothelium. MAYO CLINIC PROCEEDINGS, 96(6), 1672-1672 [10.1016/j.mayocp.2021.04.004].
Availability:
This version is availablehttp://hdl.handle.net/11365/1142670 since 2021-04-22T23:45:44Z
Published:
DOI:10.1016/j.mayocp.2021.04.004
Terms of use:
Open Access
The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license. For all terms of use and more information see the publisher's website.

(Article begins on next page)

Journal Pre-proof

COVID-19: Precision Medicine and Vascular Endothelium

Gerardo Tricarico, MD, Valter Travagli, PharmD

PII: S0025-6196(21)00314-1

DOI: https://doi.org/10.1016/j.mayocp.2021.04.004

Reference: JMCP 3403

To appear in: Mayo Clinic Proceedings

Received Date: 25 February 2021

Accepted Date: 12 April 2021

Please cite this article as: Tricarico G, Travagli V, COVID-19: Precision Medicine and Vascular Endothelium, *Mayo Clinic Proceedings* (2021), doi: https://doi.org/10.1016/j.mayocp.2021.04.004.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Mayo Foundation for Medical Education and Research

Mayo Clinic Proceedings

MANO CLINIC

COVID-19: Precision Medicine and Vascular Endothelium

Authors: Gerardo TRICARICO, MD^{1,2} and Valter TRAVAGLI, PharmD^{3,*}

¹ COVID1 Unit, Presidio Ospedaliero Sant'Andrea, Vercelli, Italy

² UCM United Campus of Malta, Msida, Malta

³ Università degli Studi di Siena, Dipartimento di Biotecnologie, Chimica e Farmacia – Dipartimento di Eccellenza Nazionale 2018-2022, Siena, Italy

*Corresponding author:

Valter TRAVAGLI, PharmD

Università degli Studi di Siena, Dipartimento di Biotecnologie, Chimica e Farmacia – Dipartimento di Eccellenza Nazionale 2018-2022, Viale Aldo Moro, 2 – 53100 Siena, Italy

Phone: +39 0577 234317

Fax: + 39 0577 234299

Email: valter.travagli@unisi.it

Disclosure: G. Tricarico and V. Travagli declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Letter to the Editor

COVID-19: Precision Medicine and Vascular Endothelium

To the Editor: We read with care and interest the original article from Pereira et al. about the development of a precision medicine approach to the COVID-19 pandemic.¹

We appreciate very much the specialist explanation about the demographic (such as age, race, ethnicity, sex) and biological variables (such as ACE2 expression, immune regulation, body mass index and genetics) that may characterize the high-risk patient and they can serve for optimizing hospitalization, vaccination and targeted drug therapy.

However, "predictive algorithms may help in individualizing targeted therapy including hospitalization and assist in the logistics of vaccine administration" only if all key factors are included. In our opinion, it is of paramount importance to introduce the vascular endothelium into the discussion.² In fact, endothelial damage to various organs were highlighted by autopsy outcomes³ and severe SARS-CoV-2 infection could have a more complete and significant interpretation evaluating integrity of endothelial glycocalyx.⁴

In conclusion, the recognition of the whole COVID-19 host/genetic factors that contribute to COVID-19 susceptibility and subsequent pathogenesis advocates the use of precision medicine in better designing clinical trials and in treatment of the disease.⁵

Gerardo TRICARICO, MD Presidio Ospedaliero Sant'Andrea, Vercelli, Italy

Valter TRAVAGLI, PharmD Università degli Studi di Siena Siena, Italy

References

1. Pereira NL, Ahmad F, Byku M, et al. COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. Mayo Clin Proc. 2021;96(2):446-463. doi:10.1016/j.mayocp.2020.11.024

2. Tricarico G, Zavan B, Travagli V. Clinical evidence and therapeutic treatments at the time of the coronaviruses responsible for SARS: a perspective and points of view with a focus on vascular endothelium. Coronaviruses 2021; 2: 1. https://doi.org/10.2174/2666796702666210223155317

3. Maccio U, Zinkernagel AS, Shambat SM, Zeng X, Cathomas G, Ruschitzka F, et al. SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine. 2021 Jan;63:103182. doi: 10.1016/j.ebiom.2020.103182. Epub 2021 Jan 7. PMID: 33422990; PMCID: PMC7808909.

4. Yamaoka-Tojo M. Vascular Endothelial Glycocalyx Damage in COVID-19. Int J Mol Sci. 2020 Dec 19;21(24):9712. doi: 10.3390/ijms21249712. PMID: 33352699; PMCID: PMC7766512.

5. Thierry AR. Host/genetic factors associated with COVID-19 call for precision medicine. Precision Clinical Medicine, 3(3), 2020, 228–234

© 2021 Mayo Foundation for Medical Education and Research. *Mayo Clin Proc.* 2021;96(x):xx-xx.